<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979221</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0157</org_study_id>
    <nct_id>NCT04979221</nct_id>
  </id_info>
  <brief_title>Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19</brief_title>
  <official_title>Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controled open label clinical trial conducted in patients with hypoxemic&#xD;
      respiratory failure admitted to the ICU and requiring ventilatory support (invasive or&#xD;
      non-invasive) is to evaluate whether treatment with cyproheptadine, a serotonin receptor&#xD;
      antagonist, compared to usual care, increases the number of ventilator-free days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some studies have shown increased platelet activation and reactivity in patients with&#xD;
      COVID-19. This platelet activation is associated with serotonin release. Some characteristics&#xD;
      observed during the evolution of COVID-19 may be associated with these increased levels of&#xD;
      serotonin. In this scenario, the antagonism of the action of serotonin could improve the&#xD;
      clinical course of patients affected by COVID-19. Cyprohepatdine is an anti-serotonergic&#xD;
      antihistamine drug with a long track record of safety and tolerability.&#xD;
&#xD;
      Investigators will randomize 274 patients who have tested positive for COVID-19 and who will&#xD;
      be admitted to the ICU requiring ventilatory support (invasive or non-invasive).&#xD;
&#xD;
      Patients will be randomized to a 1:1 ratio for receiving usual care + cyproheptadine (8mg&#xD;
      three times a day for 10 days) or usual care.&#xD;
&#xD;
      Patients will be followed until discharge to determine length of stay in the ICU and&#xD;
      hospital, mortality in the ICU and hospital and days free from ventilatory support during the&#xD;
      first 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilatory support</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days free from ventiltory support during the first 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Duration of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality during 28 days</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Mortality</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the intensive care unit</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the hospital</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Cyproheptadine and usual care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to the intervention group will receive cyproheptadine within 6 hours after randomization, at a dose of 8mg every 8 hours for 10 days.&#xD;
Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproheptadine</intervention_name>
    <description>Cyproheptadine 8mg three times a day during 10 days</description>
    <arm_group_label>Cyproheptadine and usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive PCR for SARS-Cov-2&#xD;
&#xD;
          -  ICU admission &lt; 48 hours&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Need for invasive or non-invasive ventilatory support (non-invasive ventilation or&#xD;
             high-flow nasal cannula) &lt; 48 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Refusal to sign the informed consent form&#xD;
&#xD;
          -  Expected death in the next 24 hours&#xD;
&#xD;
          -  Patients taking routinely SSRI or monoamine oxidase inhibitor therapy&#xD;
&#xD;
          -  Impossibility of using the enteral route&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  History of adverse reaction to antihistamines or to cyproheptadine&#xD;
&#xD;
          -  Readmission to the ICU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcio M Boniatti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcio M Boniatti, PhD</last_name>
    <phone>55 51 3359 8000</phone>
    <email>mboniatti@hcpa.edu.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clínica de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcio M Boniatti, PhD</last_name>
      <phone>55 51 33598000</phone>
      <email>mboniatti@hcpa.edu.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Márcio Manozzo Boniatti</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproheptadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

